Genmab A earnings were $1.1B for the trailing 12 months ending Dec 31, 2024, with 72.6% growth year over year. The latest GMAB earnings report on Dec 31, 2024 announced Q4 2024 earnings of $536.3M, up 187.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GMAB reported annual earnings of $1.1B, with 69.7% growth.
GMAB past earnings growth
How has GMAB's earnings growth performed historically?
On GMAB's earnings call on Invalid Date, Genmab A (NASDAQ: GMAB) reported Q4 2024 earnings per share (EPS) of $0.84, up 427.04% year over year. Total GMAB earnings for the quarter were $536.26 million. In the same quarter last year, Genmab A's earnings per share (EPS) was $0.16.
As of the last Genmab A earnings report, Genmab A is currently profitable. Genmab A's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $1.09 billion, a 69.68% increase year over year.
What was GMAB's earnings growth in the past year?
As of Genmab A's earnings date in Invalid Date, Genmab A's earnings has grown 72.64% year over year. This is 60.64 percentage points higher than the US Biotechnology industry earnings growth rate of 12%. GMAB earnings in the past year totalled $1.10 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.